Docoh
Loading...

GLPG Galapagos

News

From Benzinga Pro
Galapagos Completes Patient Recruitment For MANGROVE Phase 2 Trial With GLPG2737 In Polycystic Kidney Disease
22 Nov 21
Biotech, News, General
MANGROVE is a randomized, double-blind, placebo-controlled trial evaluating a once-daily oral dose of GLPG2737 (NCT04578548). The drug candidate or placebo is administered for 52 weeks, followed by an open-label
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $65
8 Nov 21
News, Price Target, Analyst Ratings
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from $64 to $65.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
6 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
5 Oct 21
Biotech, News, Health Care, General
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
5 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4)
Galapagos Reports Results From 2 Post Ad-Hoc Analyses From SELECTION, SELECTION LTE Studies At United European Gastroenterology Week Congress Oct. 3-5, 2021
4 Oct 21
Biotech, News, Eurozone, FDA, Markets, General
Scientific Games Corporation (NASDAQ:SGMS) ("Scientific Games" or the "Company") announced it won a 10-year base contract from the Pennsylvania Lottery (or the "Lottery") to
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
4 Oct 21
Biotech, News, Health Care, Contracts, Movers, Trading Ideas, General
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
1 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep 21
Biotech, Earnings, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep 21
Biotech, M&A, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28)
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep 21
Biotech, M&A, News, Penny Stocks, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
Galapagos Reports Positive CHMP Opinion For Jyseleca For Treatment Of Adults With Moderately To Severely Acute Ulcerative Colitis
17 Sep 21
Biotech, News, FDA, General
Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca®

Press releases

From Benzinga Pro
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
22 Nov 21
News, Press Releases
Mechelen, Belgium; 22 November 2021, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
15 Nov 21
Press Releases
Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca® (filgotinib 200mg tablets)
Galapagos reports commercial and operational progress at Q3 financial results
4 Nov 21
News, Press Releases
First nine months 2021 financial results: Group revenues of €317.9 millionOperating loss of €175.7 millionNet loss of €119.6 millionCash and current financial investments of €4.9 billion on 30 September 2021
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
4 Oct 21
Press Releases
Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE)Treatment with filgotinib 200mg resulted in
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease
4 Oct 21
Press Releases
1,374 patients enrolled into the phase 3 study across 369 global sitesTopline data anticipated in H1 2023Galapagos will assume responsibility for the DIVERSITY study Mechelen, Belgium; 4 October 2021, 07.01 CET;
Galapagos increases share capital through subscription right exercises
20 Sep 21
News, Press Releases
Mechelen, Belgium; 20 September 2021, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 7,600
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
17 Sep 21
Press Releases
Mechelen, Belgium; 17 September 2021; 13.15 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued